PSORS13
MCID: PSR018
MIFTS: 51

Psoriasis 13 (PSORS13)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Psoriasis 13

MalaCards integrated aliases for Psoriasis 13:

Name: Psoriasis 13 57 11 73 14
Psoriasis 13, Susceptibility to 57 28 5
Psors13 57 11 73
Psoriasis Vulgaris 73 71
Psoriasis 73 71
Psoriasis, Susceptibility to, Type 13 38
Psoriasis Susceptibility 13 57
Pv 73

Classifications:



External Ids:

Disease Ontology 11 DOID:0111287
OMIM® 57 614070
OMIM Phenotypic Series 57 PS177900
MeSH 43 D011565
MedGen 40 C3279754
UMLS 71 C0033860 C0263361

Summaries for Psoriasis 13

UniProtKB/Swiss-Prot: 73 A common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis.

MalaCards based summary: Psoriasis 13, also known as psoriasis 13, susceptibility to, is related to psoriasis 14, pustular and psoriasis 3, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Psoriasis 13 is TRAF3IP2 (TRAF3 Interacting Protein 2). The drugs Infliximab and Metformin have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and endothelial, and related phenotype is integument.

Disease Ontology: 11 A psoriasis that has material basis in variation in TRAF3IP2 on chromosome 6q21.

More information from OMIM: 614070 PS177900

Related Diseases for Psoriasis 13

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13 Psoriasis 15

Diseases related to Psoriasis 13 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1493)
# Related Disease Score Top Affiliating Genes
1 psoriasis 14, pustular 32.8 IL36RN CARD14
2 psoriasis 3 32.2 IL36RN CARD14
3 psoriasis 4 32.1 LCE3A CARD14
4 psoriasis 15 32.0 IL36RN CARD14
5 pustulosis of palm and sole 31.9 IL36RN CARD14
6 impetigo herpetiformis 31.7 IL36RN CARD14
7 geographic tongue 31.5 IL36RN CARD14
8 acrodermatitis 30.6 IL36RN CARD14
9 pityriasis rubra pilaris 30.5 IL36RN CARD14
10 impetigo 30.5 IL36RN CARD14
11 discoid lupus erythematosus 30.4 TRAF3IP2-AS1 TRAF3IP2
12 psoriasis 7 29.8 TRAF3IP2 CARD14
13 periodic fever, familial, autosomal dominant 29.2 IL36RN CARD14
14 psoriatic arthritis 11.8
15 pustular psoriasis 11.7
16 guttate psoriasis 11.6
17 tranebjaerg svejgaard syndrome 11.5
18 psoriatic juvenile idiopathic arthritis 11.5
19 psoriasis 6 11.4
20 psoriasis 10 11.4
21 psoriasis 5 11.4
22 periodontitis, aggressive, 1 11.4
23 psoriasis 12 11.4
24 psoriasis 8 11.4
25 psoriasis 15, pustular 11.4
26 psoriasis 9 11.4
27 spondyloarthropathy 1 11.4
28 skin disease 11.2
29 arthritis 11.2
30 juvenile rheumatoid arthritis 11.1
31 dermatitis 11.1
32 vitiligo-associated multiple autoimmune disease susceptibility 1 11.0
33 parapsoriasis 11.0
34 nail disorder, nonsyndromic congenital, 1 11.0
35 singleton-merten syndrome 1 11.0
36 autoinflammatory syndrome, familial, with or without immunodeficiency 11.0
37 dermatitis, atopic 11.0
38 acute generalized exanthematous pustulosis 10.9
39 mental retardation and psoriasis 10.9
40 subacute cutaneous lupus erythematosus 10.9
41 chronic recurrent multifocal osteomyelitis 10.9
42 autoimmune disease 10.9
43 fanconi-bickel syndrome 10.9
44 singleton-merten syndrome 10.9
45 combined cellular and humoral immune defects with granulomas 10.8
46 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.8
47 hypotrichosis-osteolysis-periodontitis-palmoplantar keratoderma syndrome 10.8
48 singleton-merten syndrome 2 10.8
49 primary cutaneous amyloidosis 10.8
50 glycogen storage disease due to lactate dehydrogenase deficiency 10.8

Graphical network of the top 20 diseases related to Psoriasis 13:



Diseases related to Psoriasis 13

Symptoms & Phenotypes for Psoriasis 13

Clinical features from OMIM®:

614070 (Updated 08-Dec-2022)

UMLS symptoms related to Psoriasis 13:


pruritus; exanthema; psoriasiform rash

MGI Mouse Phenotypes related to Psoriasis 13:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.02 CARD14 IL36RN MCOLN1 TMEM79 TRAF3IP2

Drugs & Therapeutics for Psoriasis 13

Drugs for Psoriasis 13 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4 170277-31-3
2
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
3
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
4
Dapsone Approved, Investigational Phase 4 80-08-0 2955
5
Vedolizumab Approved Phase 4 943609-66-3
6
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
7
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
9
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
10
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
11
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
12
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
13
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
14
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
15
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
16
Desoximetasone Approved Phase 4 382-67-2 5311067
17
Sorbitol Approved, Investigational Phase 4 69-65-8, 50-70-4 453 6251 5780
18
Clocortolone Approved Phase 4 34097-16-0, 4828-27-7 5311052
19
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
20
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
21
Ustekinumab Approved, Investigational Phase 4 815610-63-0
22
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
23
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
24
Ixekizumab Approved, Investigational Phase 4 1143503-69-8
25
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
26
Calcipotriol Approved Phase 4 112965-21-6 5288783
27
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
28
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 2791 5311051 32798
29
Adalimumab Approved, Experimental Phase 4 331731-18-1
30
Alefacept Approved, Investigational, Withdrawn Phase 4 222535-22-0
31
Capsaicin Approved Phase 4 404-86-4 1548943
32
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
33
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
34
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
35
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
36
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
38
Trichostatin A Experimental Phase 4 58880-19-6 5562 444732
39 Antiprotozoal Agents Phase 4
40 Antiparasitic Agents Phase 4
41 Antimalarials Phase 4
42 Trace Elements Phase 4
43 Vasoconstrictor Agents Phase 4
44 Micronutrients Phase 4
45 Calciferol Phase 4
46 Hydrocortisone 17-butyrate 21-propionate Phase 4
47 Pharmaceutical Solutions Phase 4
48 Chelating Agents Phase 4
49 Anti-Bacterial Agents Phase 4
50 Anesthetics Phase 4

Interventional clinical trials:

(show top 50) (show all 1637)
# Name Status NCT ID Phase Drugs
1 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
2 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
3 Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT). Unknown status NCT03307447 Phase 4 Secukinumab
4 A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis Unknown status NCT03408756 Phase 4 methotrexate
5 Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism: A Double-Blind, Randomized, Placebo-Controlled Study Unknown status NCT03629639 Phase 4 Metformin
6 A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis Unknown status NCT03553433 Phase 4 Apremilast 30mg;Placebo Oral Tablet
7 Palmoplantar Psoriasis: Evaluating Efficacy and Clinical Photography With Brodalumab in Palmoplantar Psoriasis Unknown status NCT04622033 Phase 4
8 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
9 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
10 Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients Unknown status NCT04372277 Phase 4 Enstilar
11 An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab Unknown status NCT03827876 Phase 4 Enstilar 0.005%-0.064% Topical Foam
12 A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis. Unknown status NCT04347473 Phase 4 Ilumya Injectable Product
13 Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated With Biologic Agents. Unknown status NCT04119102 Phase 4 Duobrii
14 Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis After Combination Treatment of Lexette and Sorilux for 2 Weeks Unknown status NCT04571151 Phase 4 LEXETTE 0.05% Topical Foam;Sorilux 0.005 % Topical Foam
15 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
16 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
17 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
18 Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis Unknown status NCT02829424 Phase 4 Methotrexate;Methotrexate Placebo
19 A Single Center Study to Evaluate the Effectiveness and Safety of Add on Enstilar® in Patients Using OTEZLA® for Moderate to Severe Plaque Psoriasis Unknown status NCT03587194 Phase 4 Otezla
20 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
21 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
22 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
23 Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis Unknown status NCT03453190 Phase 4
24 Prevalence, Pattern and Disease Course og Arthritis and Enthesitis in Patients With Psoriasis, and Effect of Apremilast in Subclinical, US-defined Psoriatic Arthritis - a Population Based Study Applying Clinical, Ultrasonic, MRI and Patient-reported Outcomes Unknown status NCT04515732 Phase 4 Apremilast Oral Tablet
25 Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis Unknown status NCT03478280 Phase 4 Brodalumab;Placebos
26 Studying the Effect of Methotrexate Alone Versus Methotrexate and Vitamin D on the Cardiovascular Risk of Psoriatic Patients Unknown status NCT03904680 Phase 4 Methotrexate;Vitamin D
27 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
28 The Maintenance Effect of Enstilar Foam in Combination With Otezla Unknown status NCT04555707 Phase 4 Apremilast 30mg;calcipotriene and betamethasone dipropionate
29 Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions Unknown status NCT03629379 Phase 4 Ustekinumab;Vedolizumab
30 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
31 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
32 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
33 Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris Completed NCT01707043 Phase 4 Taclonex
34 A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris Completed NCT00640393 Phase 4 Etanercept
35 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. Completed NCT02733874 Phase 4 Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
36 Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris Completed NCT02004574 Phase 4 Calcipotriol/betamethasone dipropionate gel
37 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
38 Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris Completed NCT00216892 Phase 4 Calcipotriol, (calcipotriol + betamethasone)
39 A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris Completed NCT00248456 Phase 4 Calcipotriol plus betamethasone dipropionate ointment
40 A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Completed NCT03331835 Phase 4 Fumaric acid esters
41 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Completed NCT03022617 Phase 4 Apremilast
42 A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis Completed NCT02125279 Phase 4 Calcitriol
43 Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis Completed NCT03348462 Phase 4 ethosomal preparation of anthralin;liposomal preparation of anthralin
44 Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Completed NCT02533973 Phase 4 Xamiol® gel;Daivonex® scalp solution
45 Evaluation of Nail Psoriasis Severity Index (NAPSI) and Modified Napsi in Patients With Nail Psoriasis Treated With Acitretin Completed NCT00723437 Phase 4 acitretin
46 Comparison of the Performance of Subjective or Objective Psoriasis Severity Assessment Tools for the Assessment of the Improvement of Psoriasis After Oral Cyclosporine A or Methotrexate Treatment Completed NCT02655705 Phase 4 Cyclosporine A;Methotrexate
47 Randomised, Open-label Preliminary Study to Assess the Effects of 2 Regimens of Etanercept on Nail and Skin Symptoms in Patients With Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept
48 A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis Completed NCT03942042 Phase 4 Ixekizumab
49 A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions With Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated With the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI) Completed NCT01511315 Phase 4 Ustekinumab
50 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept

Search NIH Clinical Center for Psoriasis 13

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acitretin
alefacept
Aloe vera preparation
Anthralin
ANTHRALIN PWDR
Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
calcipotriene
Calcitriol
Cholecalciferol
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Cod Liver Oil
Colloid sulfur
Cyclosporine
Etretinate
Fish Liver Oils
fluocinolone
Fluocinolone Acetonide
hydroxyurea
Methotrexate
Methotrexate Sodium
Methoxsalen
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Thioguanine
Trioxsalen

Genetic Tests for Psoriasis 13

Genetic tests related to Psoriasis 13:

# Genetic test Affiliating Genes
1 Psoriasis 13, Susceptibility to 28 TRAF3IP2

Anatomical Context for Psoriasis 13

Organs/tissues related to Psoriasis 13:

MalaCards : Skin, Liver, Endothelial, T Cells, Neutrophil, Monocytes, Pituitary

Publications for Psoriasis 13

Articles related to Psoriasis 13:

(show top 50) (show all 30648)
# Title Authors PMID Year
1
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. 62 57 5
20953188 2010
2
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. 62 57 5
20953186 2010
3
CIKS/Act1-mediated signaling by IL-17 cytokines in context: implications for how a CIKS gene variant may predispose to psoriasis. 62 5
22581863 2012
4
An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. 5
24120361 2013
5
Injection site reactions due to the use of biologics in patients with psoriasis: A retrospective study. 62
36444279 2023
6
Evaluation of serum vascular endothelial growth factor level and findings of nailfold capillaroscopy by dermatoscope in the differential diagnosis of palmoplantar psoriasis and palmoplantar eczema. 62
36195239 2023
7
Efficient local delivery of FK506 using blocking patches in psoriasis. 62
36274404 2023
8
The risk of COVID-19 in patients with psoriasis: A retrospective cohort study. 62
36305697 2022
9
Biologics for psoriasis: is there any unmet need left? 62
36461935 2022
10
Subacute exposure to bisphenol F diglycidyl-ether (BFDGE) induces chronic dermatitis characterized by psoriasis-like skin inflammation in mice. 62
36453187 2022
11
[[Translated article]]Epidemiology and Geographic Distribution of Generalized Pustular Psoriasis in Spain: A National Population-Based Study of Hospital Admissions from 2016 to 2020. 62
36464011 2022
12
Deucravacitinib in the treatment of psoriasis. 62
36453809 2022
13
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1). 62
36456890 2022
14
Pustular Psoriasis. 62
36464467 2022
15
[[Translated article]]RF - Role of the Mediterranean Diet in the Treatment of Psoriasis. 62
36464008 2022
16
TRIM22 actives PI3K/Akt/mTOR pathway to promote psoriasis through enhancing cell proliferation and inflammation and inhibiting autophagy. 62
36170453 2022
17
Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis. 62
36208408 2022
18
Pathogenesis, multi-omics research, and clinical treatment of psoriasis. 62
36209691 2022
19
Examining worldwide postmarketing suicides from biologics used for psoriasis with a focus on brodalumab: A cross-sectional analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS). 62
36248199 2022
20
Restless legs syndrome in patients with psoriasis: association with inflammation and sleep quality. 62
36468846 2022
21
Dupilumab-induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression. 62
36468831 2022
22
The epidermal immune microenvironment plays a dominant role in psoriasis development, as revealed by mass cytometry. 62
36348078 2022
23
Assessment of efficacy and safety of UV-based therapy for psoriasis: a network meta-analysis of randomized controlled trials. 62
34989291 2022
24
Maternal and neonatal outcomes of births to women with psoriasis: a population-based cohort of 13 million births. 62
34961404 2022
25
Genetic variants in IL-17A rs10484879 and serum levels of IL-17A are associated with psoriasis risk. 62
34853870 2022
26
Association between sodium-glucose co-transporter 2 inhibitors and risk of psoriasis in patients with diabetes mellitus: a nationwide population-based cohort study. 62
35997237 2022
27
Low prevalence of patients diagnosed with psoriasis in Nuuk: a call for increased awareness of chronic skin disease in Greenland. 62
35467496 2022
28
Trajectories of systemic agent use and associated depression- and anxiety-related health care costs among patients with psoriasis. 62
35996750 2022
29
Artificial intelligence for the automated single-shot assessment of psoriasis severity. 62
35739649 2022
30
ROS-sensitive calcipotriol nano-micelles prepared by methoxypolyethylene glycol (mPEG) - modified polymer for the treatment of psoriasis. 62
35748409 2022
31
Ustekinumab plus dupilumab in the treatment of concomitant psoriasis and prurigo nodularis. 62
35857380 2022
32
Cytokine Modulators in Plaque Psoriasis - A Review of Current and Prospective Biologic Therapeutic Approaches. 62
36248203 2022
33
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry. 62
36331713 2022
34
Female sexual dysfunction in psoriasis: a systematic review and meta-analysis using the Female Sexual Function Index. 62
36456639 2022
35
Psoriasis in the transplant population. 62
36459192 2022
36
Lenalidomide attenuates IMQ-induced inflammation in a mouse model of psoriasis. 62
36270258 2022
37
Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trial. 62
36116584 2022
38
Disparities in psoriasis clinical trials: A cross-sectional analysis. 62
36113618 2022
39
Practices and perspectives on medical cannabis and cannabinoids: A survey of the National Psoriasis Foundation Medical Advisory Board. 62
36017106 2022
40
The protective effect of proanthocyanidins on the psoriasis-like cell models via PI3K/AKT and HO-1. 62
36178125 2022
41
A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. 62
36271222 2022
42
How important is subjective well-being for patients? A qualitative interview study of people with psoriasis. 62
35948788 2022
43
The link between total antioxidant status, total oxidant status, arylesterase activity, and subgingival microbiota in psoriasis patients. 62
35906956 2022
44
Cognitive impairment in psoriasis patients: a systematic review of case-control studies. 62
35945395 2022
45
Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach. 62
35609147 2022
46
Psoriasis treatment: no more room on the summit? 62
36065496 2022
47
Comment on: 'Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?' 62
36006173 2022
48
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab. 62
35895852 2022
49
Clinical characteristics and outcomes of patients with COVID-19 and psoriasis. 62
36000295 2022
50
Current trend in the treatment of generalized pustular psoriasis in Japan: Results from a questionnaire-based epidemiological study. 62
35876178 2022

Variations for Psoriasis 13

ClinVar genetic disease variations for Psoriasis 13:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TRAF3IP2, TRAF3IP2-AS1 NM_147686.4(TRAF3IP2):c.28G>A (p.Asp10Asn) SNV Risk Factor
30630 rs33980500 GRCh37: 6:111913262-111913262
GRCh38: 6:111592059-111592059
2 TRAF3IP2, TRAF3IP2-AS1, LOC114803478 NM_147686.4(TRAF3IP2):c.819C>G (p.His273Gln) SNV Uncertain Significance
626192 rs144405088 GRCh37: 6:111912471-111912471
GRCh38: 6:111591268-111591268
3 TRAF3IP2, TRAF3IP2-AS1 NM_147686.4(TRAF3IP2):c.869T>G (p.Ile290Ser) SNV Uncertain Significance
1675146 GRCh37: 6:111901553-111901553
GRCh38: 6:111580350-111580350

UniProtKB/Swiss-Prot genetic disease variations for Psoriasis 13:

73
# Symbol AA change Variation ID SNP ID
1 TRAF3IP2 p.Asp19Asn VAR_047349 rs33980500

Expression for Psoriasis 13

Search GEO for disease gene expression data for Psoriasis 13.

Pathways for Psoriasis 13

GO Terms for Psoriasis 13

Biological processes related to Psoriasis 13 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor-mediated signaling pathway GO:0033209 8.92 TRAF3IP2 CARD14

Sources for Psoriasis 13

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....